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A B S T R A C T
Purpose
ESR1mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer.We
assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III ran-
domized trials that represent the development of the current standard therapy for estrogen
receptor–positive advanced breast cancer.
Materials and Methods
In a prospective-retrospective analysis,weassessedESR1mutations in available archived baseline plasma
from the SoFEA (Study of Faslodex Versus ExemestaneWith or Without Arimidex) trial, which compared
exemestane with fulvestrant-containing regimens in patients with prior sensitivity to nonsteroidal AI
and in baseline plasma from the PALOMA3 (Palbociclib Combined With Fulvestrant in Hormone
Receptor–Positive HER2-Negative Metastatic Breast Cancer After Endocrine Failure) trial, which com-
pared fulvestrant plus placebo with fulvestrant plus palbociclib in patients with progression after receiving
prior endocrine therapy. ESR1 mutations were analyzed by multiplex digital polymerase chain reaction.
Results
In SoFEA, ESR1mutations were found in 39.1% of patients (63 of 161), of whom 49.1% (27 of 55) were
polyclonal, with rates of mutation detection unaffected by delays in processing of archival plasma. Patients
withESR1mutationshad improvedprogression-freesurvival (PFS) after taking fulvestrant (n=45) compared
with exemestane (n=18; hazard ratio [HR], 0.52; 95%CI, 0.30 to 0.92;P= .02),whereas patientswithwild-
type ESR1 had similar PFS after receiving either treatment (HR, 1.07; 95% CI, 0.68 to 1.67; P = .77). In
PALOMA3,ESR1mutationswere found in theplasmaof 25.3%of patients (91of 360), ofwhom28.6% (26
of 91) were polyclonal, with mutations associated with acquired resistance to prior AI. Fulvestrant plus
palbociclib improved PFS compared with fulvestrant plus placebo in both ESR1mutant (HR, 0.43; 95% CI,
0.25 to 0.74; P = .002) and ESR1 wild-type patients (HR, 0.49; 95% CI, 0.35 to 0.70; P , .001).
Conclusion
ESR1 mutation analysis in plasma after progression after prior AI therapy may help direct choice of
further endocrine-based therapy. Additional conﬁrmatory studies are required.
J Clin Oncol 34:2961-2968. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Targeting the estrogen receptor (ER) with endocrine
therapies was the ﬁrstmolecularly targeted treatment
of breast cancer and remains amainstay of treatment
of all stages of ER-positive disease.1-3 Approximately
75% of breast cancers are ER-positive, with endo-
crine therapy the favored initial choice for patients
who develop metastatic disease.4 In this setting, al-
most all patients will acquire endocrine resistance,
with a proportion demonstrating primary re-
sistance. Identifying therapies with activity in
tumors resistant to standard endocrine therapy
is a key therapeutic challenge.
Although diverse mechanisms of resistance
to endocrine therapy have been described, recent
evidence has identiﬁed mutations in the ER gene
(ESR1).5 ESR1 mutations occur rarely in primary
breast cancer,6 but have a high prevalence in
advanced breast cancers previously treated with
aromatase inhibitors (AIs),7-9 implying evolution
© 2016 by American Society of Clinical Oncology 2961
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through selective treatment pressure. Most ESR1 mutations occur
in hotspot regions in the ligand-binding domain of ER, resulting in
ligand-independent, constitutive ER activity.8-11 Prior research has
demonstrated that circulating tumor DNA (ctDNA) is detected in
the plasma of patients with cancer and may provide a robust,
noninvasive method for detecting ESR1 mutations.7,12-15
The most effective treatment of ESR1 mutant breast cancer is
uncertain.8,9 In a retrospective, single-center analysis, we have
demonstrated resistance to subsequent AI-based therapy in pa-
tients with ESR1 mutations in plasma.7 Preclinical studies have
reported growth inhibition of ESR1 mutant cell lines with
fulvestrant, a selective ER degrader, but with less sensitivity to
fulvestrant than wild-type ER, and there is uncertainty whether the
required doses are achieved clinically.8 Palbociclib, a CDK4/6
inhibitor, has demonstrated substantial clinical activity in com-
bination with both fulvestrant and AIs.16,17 CDK4/6 inhibition
resensitizes cells with in vitro-derived resistance to endocrine
therapy,18 and ESR1 mutant models are sensitive to combinations
of selective ER degraders with palbociclib.19
In this study, we used ctDNA analysis to identify ESR1mutant
cancers and assess the impact of mutations on the efﬁcacy of
current therapies. Baseline plasma samples were drawn from two
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Fig 1. CONSORT diagram demonstrating sam-
ples analyzed in the (A) SoFEA and (B) PALOMA3
trials. *Only samples after January 2, 2008, were
available after a ﬁre at The Royal Marsden Hospital.
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randomized phase III studies that spanned the development of
standard endocrine-based therapy for breast cancer progressing
after prior endocrine therapy.17,20 The SoFEA (Study of Faslodex
Versus Exemestane With or Without Arimidex) trial showed no
signiﬁcant difference in its primary end point of progression free
survival (PFS) between fulvestrant 250 mg, fulvestrant 250 mg plus
anastrozole, and exemestane in a population previously sensitive
to AIs.20 The PALOMA3 (Palbociclib Combined With Fulvestrant
in Hormone Receptor–Positive HER2-Negative Metastatic Breast
Cancer After Endocrine Failure) study demonstrated that palbo-
ciclib improves PFS (its primary end point) when added to ful-
vestrant 500 mg in patients with progression after receiving prior
endocrine therapy.17 From our prior retrospective study,7 we hy-
pothesized that ESR1 mutant patients would have a poor prognosis
when treated with exemestane and that prognosis would be im-
proved with fulvestrant (samples from SoFEA), with additional
improvement with palbociclib (samples from PALOMA3).
MATERIALS AND METHODS
The SoFEA study was a multicenter, randomized phase III trial in post-
menopausal women with advanced, hormone receptor–positive breast
cancer who had demonstrated prior sensitivity to AIs. Sensitivity was
deﬁned as relapse or progression after taking a nonsteroidal AI given as
adjuvant treatment for at least 12 months or as ﬁrst-line metastatic
treatment for at least 6 months.20 Patients were assigned fulvestrant
(500 mg intramuscularly on day 1, followed by 250 mg on days 15 and 29,
then every 28 days) plus anastrozole 1 mg, fulvestrant plus placebo, or
exemestane 25 mg. Baseline plasma samples were available from 162
patients of the 723 enrolled (22.4%), with no samples available before
January 2, 2008, because of a ﬁre at the Royal Marsden Hospital (Fig 1A).
The subset of patients with baseline plasma samples available had similar
characteristics, except for a longer time to relapse and a longer time
taking an AI, and outcomes similar to the rest of the study population
(Data Supplement). Written informed consent was obtained from all
participants, and ESR1 analysis was approved by the research ethics
committee.
The PALOMA3 trial was a multicenter, randomized phase III trial
assessing palbociclib and fulvestrant in premenopausal and post-
menopausal women with advanced, hormone receptor–positive breast
cancer who had progressed during prior endocrine therapy.17 Patients were
assigned 2:1 to palbociclib (125 mg orally for 3 weeks followed by 1 week
off) and fulvestrant (500 mg intramuscularly every 14 days for the ﬁrst
three injections, then 500 mg every 28 days), or matching placebo plus
fulvestrant. Premenopausal patients received goserelin for the study du-
ration. We analyzed 360 baseline plasma samples from 521 patients
(69.1%) enrolled in the PALOMA3 trial (Fig 1B). The subset of patients
with baseline plasma samples available had similar characteristics, with the
exception of prior chemotherapy exposure, and outcomes similar to the
rest of the study population (Data Supplement). Written informed consent
was obtained from all participants.
Processing of Plasma and Extraction of Circulating DNA
In the SoFEA trial, baseline blood was collected in EDTA blood
collection tubes and processed within 0 to 9 days of sample collection.
Plasma was separated by centrifugation at 1,600 g for 20 minutes. In
the PALOMA3 study, baseline blood was collected in EDTA tubes and
centrifuged within 30 minutes at 1,500 to 2,000 g for 10 minutes. Samples
were stored at 280°C until DNA extraction. DNA extraction was per-
formed using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Digital Polymerase Chain Reaction Analysis
Total free DNA was quantiﬁed from plasma using RNase P as the ref-
erence gene as previously reported7 (Data Supplement). For ESR1 mutation
analysis, we used commercially available multiplex droplet digital polymer-
ase chain reaction (ddPCR) assays for the seven most common ESR1 mu-
tations; multiplex 1 included c.1138G.C(E380Q), c.1607T.G(L536R),
c.1610A.G(Y537C), and c.1613A.G(D538G; dHsaMDXE91450042);
and multiplex 2 included c.1387T.C(S463P), c.1609T.A(Y537N), and
c.1610A.C(Y537S; dHsaMDXE65719815). ddPCR was performed on
a QX200 system (Bio-Rad, Hercules, CA) on a minimum of 1-mL plasma
equivalent for SoFEA samples and 0.5-mL for PALOMA3. A multiplex assay
was considered mutation positive if at least two ESR1 mutant droplets were
observed. The results obtained on the multiplex ddPCR were further
characterized using uniplex ddPCR assays. Mutation allele fraction and
copies per mL were calculated as previously described.21 A sample was
considered polyclonal if it was positive on both multiplexes or if separate
mutations were characterized on uniplex conﬁrmation.
Validation of Analysis of ESR1 Mutations in Archival Plasma
Samples
Archival plasma samples were available in the SoFEA trial, and we
validated the analysis of ctDNA in archival plasma, demonstrating that
archival EDTA plasma samples can be used for ctDNA analysis with ddPCR
(Data Supplement).
Statistical Analysis
In this prospective-retrospective study, the most recent clinical data
snapshots were used for both SoFEA and PALOMA3.20,22 ESR1 mutation
status was measured as a binary outcome (mutated v wild type). The
principal analysis population for both trials included all patients who were
randomly assigned on an intention-to-treat basis and had been assessed for
ESR1 status. There was no difference in efﬁcacy between the two fulvestrant
groups in the SoFEA trial, and these were merged for primary end point
analysis, as prespeciﬁed in the statistical analysis plan. P values were two
tailed and considered signiﬁcant if P was, .05 for the principal analyses of
PFS. Other analyses were exploratory and considered signiﬁcant if P was
, .01 to take multiple comparisons into account.
Survival end point comparisons were made using the log-rank test.
Hazard ratios (HRs) were obtained from Cox proportional hazards re-
gression models. The proportionality assumption of the Cox models was
tested with Schoenfeld residuals and was shown to hold for all analyses.
Survival data in PALOMA3 were stratiﬁed according to the presence or
absence of visceral disease and sensitivity to prior endocrine therapy in line
with the main trial analyses. Interaction tests were used to explore dif-
ferential effects between ESR1 mutation status and trial treatment in re-
lation to PFS. Multivariable models assessed ESR1 mutation status and
treatment group separately for each trial, adjusting for, in the case of
SoFEA, factors identiﬁed for the principal analysis, namely, time from
diagnosis to ﬁrst relapse, number of disease sites present at baseline, and
prior AI setting and time receiving an AI. Any baseline characteristics that
were statistically signiﬁcant when comparing ESR1 mutation versus wild
type were also included in the multivariable models separately for SoFEA
and PALOMA3 if they signiﬁcantly added value to the model (likelihood
ratio test P , .05). All statistical analyses were performed with Stata
(version 13.1; STATA, College Station, TX) or GraphPad Prism (version
6.0; GraphPad Software, La Jolla, CA).
RESULTS
Impact of ESR1 Mutation on Sensitivity to Endocrine
Therapies in SoFEA
In SoFEA, ESR1 mutation status was successfully analyzed in
99.4% (161 of 162, representing 22.4% of all patients) of available
www.jco.org © 2016 by American Society of Clinical Oncology 2963
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baseline plasma samples, with ESR1 mutations detected in 39.1%
of samples (63 of 161). We assessed the impact of ESR1 mutations
on outcome in patients randomly assigned to receive exemestane
(n = 57) versus fulvestrant-containing (n = 104) regimens. For
patients with ESR1mutant ctDNA, the median PFSwas 2.6 months
(95% CI, 2.4 to 6.2) for patients given exemestane and 5.7 months
(95% CI, 3.0 to 8.5) for those given fulvestrant (Fig 2A; HR, 0.52;
95% CI, 0.30 to 0.92; P = .02), whereas patients with wild-type
ESR1 had a median PFS of 8.0 months (95% CI, 3.0 to 11.5) when
given exemestane and a median PFS of 5.4 months (95% CI, 3.7 to
8.1) when given fulvestrant (Fig 2B; HR, 1.07; 95%CI, 0.68 to 1.67;
P = .77). The interaction test between treatment allocation and
ESR1 mutation status was P = .07. Considering ESR1 mutation
status within the exemestane group, patients with an ESR1 mu-
tation had worse PFS than ESR1 wild type (Data Supplement; HR,
2.12; 95% CI, 1.18 to 3.81; P = .01). In the SoFEA study, the
number of deaths provided insufﬁcient statistical power to detect
a statistically signiﬁcant difference in survival curves, although the
effects of ESR1 mutation on overall survival in patients treated
with exemestane were consistent with the PFS analysis (Data
Supplement).
Impact of ESR1Mutation on Sensitivity to Palbociclib in
PALOMA3
In PALOMA3, ESR1mutation status was successfully analyzed
in 100% of available samples (360 of 360, representing 69.1% of all
patients), with ESR1mutations detected in 25.3% of patients (91 of
360). For patients with ESR1 mutant ctDNA, the median PFS was
9.4 months (95% CI, 5.3 to 11.1) for those taking fulvestrant and
palbociclib, compared with 3.6 months (95% CI, 2.0 to 5.5) for
those taking fulvestrant and placebo (Fig 3A; HR, 0.43; 95% CI,
0.25 to 0.74; P = .002). For ESR1 wild-type patients, the PFS was
9.5 months (95% CI, 9.2 to not estimable) for those taking ful-
vestrant and palbociclib and 5.4 months (95% CI, 3.5 to 7.4) for
those taking fulvestrant and placebo (Fig 3B; HR, 0.49; 95% CI,
0.35 to 0.70; P, .001). The beneﬁt from palbociclib was therefore
seen despite ESR1 mutation status (interaction P = .74). The
conﬁrmed objective response rates were not signiﬁcantly different
between the ESR1 mutant and ESR1 wild-type patients (Data
Supplement), but a negative impact of ESR1mutations on response
to fulvestrant and palbociclib cannot be excluded.
Clinical and Pathologic Associations of ESR1Mutations
With different ESR1 mutation rates observed between the
studies, we investigated which clinical and pathologic features were
associated with ESR1 mutations. SoFEA recruited a relatively ho-
mogenous population of postmenopausal women with prior sen-
sitivity to an AI, and there were no signiﬁcant differences in baseline
characteristics between patients with and without ESR1 mutations
(Data Supplement).
A more diverse population of patients whose disease had
progressed after receiving prior endocrine therapy was recruited
for PALOMA3. As in a prior retrospective study,7 ESR1 mutations
were almost exclusively found in patients with prior AI exposure
with or without tamoxifen and were rare in patients with prior
tamoxifen exposure only (Table 1; 28.9% [90 of 311] v 2.0% [one
of 49], respectively; P , .001). ESR1 mutation was associated with
sensitivity to prior endocrine therapy (sensitive to prior endocrine
therapy, 29.8% [85 of 285] v resistant, 8.0% [six of 75]; P , .001).
ESR1 mutation was signiﬁcantly associated with bone metastases
(P = .001) and prior lines of therapy for metastatic disease (P = .01;
Table 1). In multivariable analysis, ESR1mutation status remained
signiﬁcantly associated with exposure to an AI and sensitivity to
endocrine therapy, and with bone or visceral disease (Data
Supplement).
Impact of Individual Mutations and Clonality
In PALOMA3 overall, patients with ESR1 mutations had
marginal statistical signiﬁcance toward worse PFS compared with
ESR1 wild type in both univariate analysis (HR, 1.46; 95% CI, 1.06
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Fig 2. Progression-free survival (PFS) in SoFEA by ESR1 mutation status. (A) PFS of patients with ESR1 mutant cancers who received exemestane or a fulvestrant-
containing regimen. (B) PFS of patients without detected ESR1 mutation who received exemestane or a fulvestrant-containing regimen. HR, hazard ratio.
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to 2.02; P = .02; Data Supplement) and multivariable analysis
(HR, 1.49; 95% CI, 1.07 to 2.08; P = .02; Data Supplement). In
both studies, there was a predominance of mutations in D538G,
Y537N, Y537S, and E380Q (Table 2). Mutations were polyclonal
in 49.1% of ESR1 mutant samples (27 of 55) in SoFEA and in
28.6% (26 of 91) in PALOMA 3 (Data Supplement). The lower
rate of mutations and polyclonality in PALOMA3 likely reﬂects
the inclusion of patients with tamoxifen exposure and disease
with intrinsic resistance to prior endocrine therapy. In vitro,
different ESR1 mutations show varied sensitivity to fulvestrant,10
and we explored the impact of individual mutations on outcome
with fulvestrant using a post hoc combined analysis of fulvestrant
groups in both studies (fulvestrant-containing in SoFEA and
fulvestrant plus placebo in PALOMA3, n = 224). No signiﬁcant
difference was observed in PFS for the individual mutations
D538G, E380Q, or Y537S, or for patients with polyclonal versus
monoclonal mutations (all P . .1; Data Supplement), although
these analyses are limited by their exploratory nature and sample
size.
DISCUSSION
Results from this prospective-retrospective study on archival
samples demonstrate that plasma DNA analysis has potential
clinical utility for patients with advanced ER-positive breast cancer
that has progressed after prior AI therapy. In patients from the
SoFEA trial, the detection of ESR1 mutations in plasma DNA
predicted relative resistance to exemestane and relative sensitivity
to fulvestrant. In contrast, patients without ESR1 mutations de-
tected may derive further beneﬁt from exemestane, as well as
fulvestrant. Patients with ESR1 mutant cancers have a poor
prognosis,23 and the combination of palbociclib and fulvestrant
500 mg appeared to be equally effective in patients with or without
ESR1mutations (interaction test P = .74), although further studies
are required to conﬁrm the efﬁcacy of CDK4/6 inhibitors in ESR1
mutant cancer.
Our results demonstrate that archival plasma samples
collected in EDTA with substantially delayed processing can be
used for ctDNA analysis using digital polymerase chain reaction
(PCR). This technique is robust for mutation detection, despite
the release of contaminating free germline DNA from white
blood cell lysis, allowing for accurate ctDNA analysis in what are
traditionally seen as suboptimally processed samples.24 This
ﬁnding will open up large archival plasma sets linked to phase III
trials for ctDNA analysis using digital PCR. Samples were col-
lected in EDTA tubes, which chelate calcium and inhibit blood
DNases,25 and it is unknown whether the ﬁndings apply to
samples collected with alternative anticoagulants or other
methods of ESR1 detection. The ﬁnding on multivariable analysis
that detection of ESR1 mutations is associated with bone and
visceral disease may suggest limited detection in patients with
nodal or locoregional recurrence only, and this should be con-
sidered in future studies.
ESR1 mutations are a rare cause of intrinsic primary endo-
crine resistance and are observed in advanced ER-positive breast
cancer during the development of acquired secondary resistance to
AI therapy (Table 1). This is consistent with the higher rate of ESR1
mutations observed in SoFEA, where recruited patients had all
demonstrated previous clinical beneﬁt from an AI. As a conse-
quence, there were no clinical-pathologic associations of ESR1
mutations in the SoFEA cohort (Data Supplement) that could
confound the observed predictive effects (Fig 2). The prior hor-
mone sensitivity of patients in SoFEA may contribute to the re-
sidual sensitivity of ESR1 wild-type cancers to exemestane (Fig 2B;
Data Supplement), suggesting that exemestane may be still active in
tumors that have acquired resistance to nonsteroidal AIs without
selection of an ESR1 mutation.
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Fig 3. Progression-free survival (PFS) in PALOMA3 by ESR1mutation status. (A) PFS for patients with ESR1mutant cancers who received fulvestrant and placebo
or fulvestrant and palbociclib. (B) PFS for patients without detected ESR1 mutation who received fulvestrant and placebo or fulvestrant and palbociclib. HR, hazard
ratio.
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These results are consistent with our prior retrospective
analysis that showed, in a single-center retrospective series, that
patients with ESR1 mutations had a poor PFS on subsequent
AI-based therapy.7 Here, in a prospective-retrospective analysis
of SoFEA, we observed that patients with ESR1 mutations de-
tected in plasma had poor PFS on further AI therapy, speciﬁcally,
exemestane, but relatively improved PFS when treated with
fulvestrant. This provides the ﬁrst evidence of potential clini-
cal utility for the use of ESR1 plasma DNA analysis in selecting
the most appropriate endocrine therapy.26 It should be noted
that although we assessed seven different ESR1 mutations, there
may be other mutations or aberrations in ESR1, such as am-
pliﬁcation or rearrangement, that could also contribute to AI
resistance.27
Our results suggest that ESR1 mutant cancers show selective
sensitivity to fulvestrant, a drug that degrades the ER, but overall
with modestly worse PFS than wild-type cancers. This is consistent
with the ﬁnding that in vitro hotspot mutations in the ligand-
binding domain partially inhibit fulvestrant binding.10 More po-
tent receptor degraders may have the potential to further improve
with fulvestrant in ESR1 mutant cancers, and a number of such
therapies are in early clinical development. Our data conﬁrm
laboratory ﬁndings that ESR1mutant cancers continue to drive cell
cycle progression through cyclin D1 activation of CDK4/6 and that
CDK4/6 inhibition remains a highly active therapeutic approach in
ESR1 mutant cancer when combined with fulvestrant that at least
partially blocks mutant ER function.
Our study has a number of important limitations. The bi-
ologic analysis was retrospective for both studies, although to
mitigate bias, prespeciﬁed statistical analysis plans were developed.
A relatively small number of baseline samples were available from
the SoFEA trial (162), which limits the statistical power to detect
important interactions and differences, such as the interaction test
between ESR1 mutation and relative sensitivity to fulvestrant over
Table 1. Baseline Characteristics of ESR1 Mutant Patients Versus ESR1 Wild-Type Patients in PALOMA3
ESR1 Mutant
(n = 91)
ESR1 Wild Type
(n = 269) P
Median age at random assignment, years (IQR) 59 (50, 66) 56 (48, 65) .2
Hormone receptor status, No. (%)* .016
ER-positive/PR-positive 69 (75.8) 173 (64.3)
ER-positive/PR-negative 17 (18.7) 87 (32.3)
Disease-free interval (months), No. (%)† .22
# 24 6 (11.3) 38 (19.5)
. 24 47 (88.7) 157 (80.5)
Menopausal status, No. (%) .07
Premenopausal/perimenopausal 12 (13.2) 61 (22.7)
Postmenopausal 79 (86.8) 208 (77.3)
Sensitivity to prior endocrine treatment, No. (%) , .001
Yes 85 (93.4) 200 (74.4)
No 6 (6.6) 69 (25.7)
Visceral metastases, No. (%) .11
Yes 62 (68.1) 157 (58.4)
No 29 (31.9) 112 (41.6)
Bone metastases, No. (%) .001
Yes 80 (87.9) 191 (71.0)
No 11 (12.1) 79 (29.0)
Soft tissue/nodal metastases, No. (%) .04
Yes 28 (30.8) 118 (43.9)
No 63 (69.2) 151 (56.1)
Prior endocrine therapies, No. (%) , .001
Tamoxifen only 1 (1.1) 48 (17.8)
AI only 41 (45.1) 103 (38.3)
AI and tamoxifen 49 (53.9) 118 (43.9)
Prior chemotherapy, No. (%) .05
Neoadjuvant/adjuvant 32 (35.2) 123 (45.7)
Metastatic 6 adjuvant 24 (26.4) 79 (29.4)
None 35 (38.5) 67 (24.9)
Prior lines of therapy for metastatic disease, No. (%) .01
0 14 (15.4) 67 (24.9)
1 41 (45.1) 122 (45.4)
2 22 (24.2) 63 (23.4)
3+ 14 (15.4) 17 (6.3)
Disease sites, No. (%) .74
1 32 (35.2) 81 (3.1)
2 21 (23.1) 80 (29.7)
3+ 38 (41.8) 108 (40.2)
NOTE. To correct for multiple comparisons, associations with baseline characteristics were considered signiﬁcant at P , .01.
Abbreviations: AI, aromatase inhibitor; ER, estrogen receptor; IQR, interquartile range; PR, progesterone receptor.
*Local testing, analysis omits ﬁve ESR1 mutant patients and nine ESR1 wild-type patients classiﬁed as either ER-negative/PR-positive or ER/PR unknown.
†Denominator refers to patients who received adjuvant therapy (n = 53 patients with ESR1 mutation, n = 195 patients with ESR1 wild type).
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exemestane (P = .07). Further conﬁrmatory studies are required
before it could be concluded that plasma ESR1 mutation analysis
may be used to guide treatment. Although samples were collected in
multiple sites, analysis was centralized in a single laboratory. No
assessment of interlaboratory agreement has yet been conducted
with the assays, and this would be required before ESR1 digital PCR
can be used in clinical decision making. The SoFEA trial recruited
only patients with sensitivity to prior AIs, and it is unknownwhether
the results would also apply to patients who were not sensitive to
prior AIs. The exploratory analyses in this report are hypothesis
generating and will require conﬁrmation in future studies.
ESR1 mutations are found at high frequency in patients who
progress after taking prior AIs and can be analyzed relatively simply
and cheaply with digital PCR. Our data suggest that ESR1mutation
analysis may have clinical utility in directing further endocrine
therapy, although further conﬁrmatory studies are required. Our
results demonstrate that ESR1mutant and wild-type cancers seem
to be distinct subtypes of breast cancer that differ in response to
standard endocrine therapies. Future clinical trials in advanced
breast cancer might consider using plasma DNA analysis to optimize
endocrine therapy choice according to ESR1 mutation status.
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